Business
IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022
100% of dosed patients have exceeded both median and expected progression free survival (PFS). Two patients, to date, having exceeded their expected overall
About this update from In8bio, Inc.
[{"type":"text","content":"100% of dosed patients have exceeded both median and expected progression free survival (PFS). Two patients, to date, having exceeded their expected overall survival (OS). An unmethylated GBM patient remains stable at one-year post enrollment. Patient received three-repeated doses and is without disease progression, has doubled expected PFS and remains off steroids. All patients dosed demonstrating a manageable safety and tolerability profile. The first two cohorts are fully enrolled and enrollment has initiated for cohort 3, with additional clinical updates expected later in 2022. NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of gamma-delta T cell therapies, today announced updated safety and durability data from the Phase 1 clinical trial of INB-200 in patients with newly diagnosed glioblastoma multiforme (GBM). The data were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. INB-200 is a genetically engineered gamma-delta T cell product candidate that is designed to be chemotherapy resistant as part of the company’s core Drug Resistant Immunotherapy (DRI) platform. “INB-200 continues to show promising activity in this challenging disease,” said Trishna Goswami, M.D., Chief Medical Officer of IN8bio. “All patients have exceeded their expected PFS and some have exceeded expected OS even with poor prognostic factors such as MGMT unmethylated disease. We are particularly encouraged by patients in the repeated dose cohort that continue to do well, including one patient that has recently reached the 1-year progression-free milestone, demonstrating durable stable disease and having returned to work.” IN8bio is a leader in gamma-delta T cells and INB-200 was the first genetically modified gamma-delta T cell therapy to enter clinical trials. The Phase 1 trial of INB-200 completed enrollment of the first two cohorts with INB-200 being well tolerated with no dose limiting toxicities, cytokine release syndrome or neurotoxicity to date. O6-methylguanine DNA methyltransferase (MGMT) is a prognostic biomarker used in glioblastoma whereby unmethylated tumors are unresponsive to treatment with chemotherapeutic agents such as temozolomide (TMZ). INB-200 has shown early, but encouraging, observations of ...